Category Archives: Platelet Rich Plasma Injections


Takeaways from the As loss to the Giants: why is the offense cold? – Oroville Mercury-Register

The Oakland As traveled across the Bay Bridge to play the second of a two-game exhibition series against the San Francisco Giants, losing 4-2.

This short and semi-sweet summer is over, and the As are clearly shaking off some rust heading into Opening Day at home against the Los Angeles Angels at the Oakland Coliseum.

Here are some takeaways from the last exhibition game of 2020.

As offense goes cold

The As scored all of four runs in these two losses. Stephen Piscotty hit a home run on Monday, and Chad Pinder hit a two-run double off the deep centerfield bricks at Oracle Park on Tuesday that the naked eye tells us was actually a home run.

Manager Bob Melvin challenged it, and the base hit call was upheld with very little explanation.

That the As faced 18 different pitchers in 18 innings probably didnt help ignite the offensive momentum. But, rare high points and a handful of competitive at bats aside, the As put together some rough plate appearances in these exhibition games.

We would have like to have better offense here the last couple games, just didnt happen, manager Bob Melvin said. We have a good offensive team, so its not concerning. Just didnt do a whole lot.

The As struck out eight times on Monday, 12 times on Tuesday. Through these two games, theyve collected six hits and eight walks.

If the As want to avoid a slow star thats plagued them in recent years, the sluggish offense theyve displayed certainly isnt promising.

Whos on second?

For all the hullabaloo surrounding second base during Spring Training 1.0 will it be Jorge Mateo? Tony Kemp? Franklin Barreto? Vimael Machin? Will there be a platoon? Will one player play the lions share? theres a chance Pinder could be the starting second baseman against Angels left-handed starter Andrew Heaney, Melvin said.

If not at second, expect Pinder somewhere in the lineup.

Pinder has been a standout at the plate during this camp, and hes had success against left-handed pitching: slashing .252/.313/.436 with a .748 OPS and 112 wRC+ against them.

If Pinder starts at second base, what does this mean for Barreto? He had one at bat in Tuesdays game, resulting in a strikeout. None on Monday.

Barreto also caught the teams attention at camp, where he hit two quick home runs off Frankie Montas and Liam Hendriks. Coaches have said that Barreto is in need of consistent at bats to show that his high ceiling he demonstrated in the minor leagues power at the plate, speed on the bases can translate to the big leagues.

Having too much talent at one position is a good problem to have. But, somehow the second base picture got a little more fuzzy. Maybe thats OK.

Fiers got the start at Oracle Park on Tuesday, allowing two home runs to Mike Yastrzemski to lead off the first inning and Alex Dickerson in the second inning on 67 pitches in 3.1 innings. He walked Pablo Sandoval before his exit in the fourth, and Sandoval scored on a sac fly off of Joakim Soria for Fiers third earned run.

The right-handed pitchers command was a tad off and he fumbled a few signs with catcher Austin Allen.

Allen, who was named to the 30-man roster as the backup catcher, is still adjusting to Fiers unpredictability and backwards pitching style.

I made it tough on myself, Fiers said after his start. I was just wild. Wasnt throwing the ball exactly where I wanted to. Just a little erratic.

Got another five days before games actually start, for me at least.

Fiers first meaningful start should come on Sunday, where hell go head-to-head with Angels phenom Shohei Ohtani. Fiers missed the first few days of camp taking extra precautions due to exposure to Jess Luzardo, who tested positive for the coronavirus prior to report day.

Because Fiers threw bullpens during the hiatus, he wasnt too far behind his fellow rotation mates. Even if this start left a sour taste in his mouth, Fiers curveball looked season ready.

Remember, Fiers curveball had one of the best vertical drops in baseball in 2019. His 70.7 vertical drop is 7.7 inches over the league average which ranks eighth in all of baseball.

Chris Bassitt looks ready to roll

Bassitt was a step behind the rest of the starters heading into camp. He hadnt faced live hitting during the hiatus like the others had.

He caught up quickly, and looked rotation ready dealing four innings with five strikeouts in Tuesdays game. His fastball hit 95 mph and he had command of his changeup and curveball.

Hell pitch fourth out of the rotation, on Monday against the Angels.

A.J. Puk and Jess Luzardo update

Puk traveled to Los Angeles to meet with Dr. Neal ElAttrache on Monday and received platelet-rich plasma and cortisone injections in his strained left shoulder, As manager Bob Melvin said Tuesday.

Puk is likely to be sidelined for two weeks, at least, and is resting for the next 48 hours.

The left-handed pitcher was slotted to start the season in the fifth spot of Oaklands rotation, but was placed on the 10-day IL. Right-handed pitcher Daniel Mengden will fill in for him in the rotation until Puks return from injury.

Jess Luzardo is slated to pitch in either the first or second game of the regular season, Melvin announced. Luzardo, who missed the first two weeks of camp after testing positive for coronavirus, is expected to come out of the bullpen and build his arm up to pitching three innings until he can be slotted into the rotation.

Luzardo pitched to Ramn Laureano in live batting practice prior to Mondays game against the San Francisco Giants.

Other notes

View original post here:
Takeaways from the As loss to the Giants: why is the offense cold? - Oroville Mercury-Register

Takeaways from the As loss to the Giants: why is the offense cold? – Woodland Daily Democrat

The Oakland As traveled across the Bay Bridge to play the second of a two-game exhibition series against the San Francisco Giants, losing 4-2.

This short and semi-sweet summer is over, and the As are clearly shaking off some rust heading into Opening Day at home against the Los Angeles Angels at the Oakland Coliseum.

Here are some takeaways from the last exhibition game of 2020.

Mike Fiers command off, curveball solid

Fiers got the start at Oracle Park on Tuesday, allowing two home runs to Mike Yastrzemski to lead off the first inning and Alex Dickerson in the second inning on 67 pitches in 3.1 innings. He walked Pablo Sandoval before his exit in the fourth, and Sandoval scored on a sac fly off of Joakim Soria for Fiers third earned run.

The right-handed pitchers command was a tad off and he fumbled a few signs with catcher Austin Allen.

I made it tough on myself, Fiers said after his start. I was just wild. Wasnt throwing the ball exactly where I wanted to. Just a little erratic.

Got another five days before games actually start, for me at least.

Fiers first meaningful start should come on Sunday, where hell go head-to-head with Angels phenom Shohei Ohtani. Fiers missed the first few days of camp taking extra precautions due to exposure to Jess Luzardo, who tested positive for the coronavirus prior to report day.

Because Fiers threw bullpens during the hiatus, he wasnt too far behind his fellow rotation mates. Even if this start left a sour taste in his mouth, Fiers curveball looked season ready.

Remember, Fiers curveball had one of the best vertical drops in baseball in 2019. His 70.7 vertical drop is 7.7 inches over the league average which ranks eighth in all of baseball.

As offense goes cold

That the As faced 18 different pitchers in 18 innings probably didnt help ignite the offensive momentum. But, rare high points and a handful of competitive at bats aside, the As put together some rough plate appearances in these exhibition games.

The As struck out eight times on Monday, 12 times on Tuesday. Through these two games, theyve collected six hits and eight walks.

A.J. Puk and Jess Luzardo update

Puk traveled to Los Angeles to meet with Dr. Neal ElAttrache on Monday and received platelet-rich plasma and cortisone injections in his strained left shoulder, As manager Bob Melvin said Tuesday.

Puk is likely to be sidelined for two weeks, at least, and is resting for the next 48 hours.

The left-handed pitcher was slotted to start the season in the fifth spot of Oaklands rotation, but was placed on the 10-day IL. Right-handed pitcher Daniel Mengden will fill in for him in the rotation until Puks return from injury.

Jess Luzardo is slated to pitch in either the first or second game of the regular season, Melvin announced. Luzardo, who missed the first two weeks of camp after testing positive for coronavirus, is expected to come out of the bullpen and build his arm up to pitching three innings until he can be slotted into the rotation.

Luzardo pitched to Ramn Laureano in live batting practice prior to Mondays game against the San Francisco Giants.

See the article here:
Takeaways from the As loss to the Giants: why is the offense cold? - Woodland Daily Democrat

What is Trending in Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market? What are the Strategies to Boost Business in Near Years? -…

COVID-19 Updates We will be covering the overall impact of COVID -19 on the market value, market share & growth of the market and how the major players in the particular market are adapting these changes.

MarketResearchBazaar has added latest research report on Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market, this report helps to analyze top manufacturers, regions, revenue, price, and also covers Industry sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

The global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market was valued at $XX million in 2019, and MAResearch analysts predict the global market size will reach $XX million by the end of 2026, growing at a CAGR of XX% between 2019 and 2026.

Download Premium Sample of the Report: http://marketresearchbazaar.com/requestSample/24200

In this report, the study analysis was given on a worldwide scale, for instance, present and traditional Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapiesgrowth analysis, competitive analysis, and also the growth prospects of the central regions. The report gives an exhaustive investigation of this market at country &, regional levels, and provides an analysis of the industry trends in each of the sub-segments, from sales, revenue and consumption. A quantitative and qualitative analysis of the main players in related regions is introduced, from the perspective of sales, revenue and price.

According to Research, the global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market was valued at USD xxx million in 2019, and it is expected to reach a value of USD xxx million by 2026, at a CAGR of xx% over the forecast period 2021-2026. Correspondingly, the forecast analysis of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies industry comprises of Asia, North America, South America, Middle East and Africa, Europe, with the sales and revenue data in each of the sub-segments.

At the upcoming section, this report discusses industrial policy, economic environment, in addition to the fabrication processes and cost structures of the industry. And this report encompasses the fundamental dynamics of the market which include drivers, opportunities, and challenges faced by the industry. Additionally, this report showed a keen market study of the main consumers, raw material manufacturers and distributors, etc.

Geographically, this report is segmented into several key Regions, with production, consumption, revenue (M USD), market share and growth rate of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies in these regions, from 2014 to 2026 (forecast), covering

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

South America (Brazil, Argentina, Columbia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer, the top players including

Orange County Hair Restoration Center

Colorado Surgical Center&, Hair Institute

Evolution Hair Loss Institute

Hair Sciences Center of Colorado

Hair Transplant Institute of Miami

Anderson Center for Hair

Virginia Surgical Center

Savola Aesthetic Dermatology Center

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

Platelet Rich Plasma Injections

Stem Cell Therapy

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies for each application, including

Dermatology Clinics

Hospitals

If you have any special requirements, please let us know and we will offer you the report as you want.

Enquiry Before Buying: http://marketresearchbazaar.com/enquiry/24200

Major Point of TOC:

Chapter One: Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Overview

Chapter Two: Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Segment Analysis by Player

Chapter Three: Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Segment Analysis by Type

Chapter Four: Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Segment Analysis by Application

Chapter Five: Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Segment Analysis by Sales Channel

Chapter Six: Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Segment Analysis by Region

Chapter Seven: Profile of Leading Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Players

Chapter Eight: Upstream and Downstream Analysis of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies

Chapter Nine: Development Trend of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies (2020-2029)

Chapter Ten: Appendix

Read Full Report: http://marketresearchbazaar.com/requestSample/24200

If you have any special requirements, please let us know and we will offer you the report as you want.

About (Market Research Bazaar):

Market Research Bazaar (MRB)- a part of VRRB Reports LLP is an overall Market Research and consulting organization. We give unparalleled nature of offering to our clients present all around the world crosswise over industry verticals. Market Research Bazaar has aptitude in giving profound jump showcase understanding alongside advertise knowledge to our clients spread across over different endeavours.

Media Contact:

UK: +442070973908

US: +13156360953

India: +919548234540

Email:[emailprotected]

Website:http://marketresearchbazaar.com/

Blog:http://marketresearchbazaar.com/blogs

Follows to Twitter : https://twitter.com/BazaarMrb

Follows to Linkdin : https://www.linkedin.com/company/market-research-bazaar-vrrb/

See the article here:
What is Trending in Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market? What are the Strategies to Boost Business in Near Years? -...

Platelet-Rich Plasma for the Knee: Does It Work?

Key points

Injections of platelet-rich plasma (PRP) are a novel treatment for managing pain related to osteoarthritis (OA) of the knee. Researchers are still investigating this option.

Some PRP preparations have approval from the Food and Drug Administration (FDA), but approval does not yet cover the use of PRP in OA of the knee. Nevertheless, some clinics may offer it off-label.

Current guidelines from the American College of Rheumatology and the Arthritis Foundation (ACR/AF) strongly recommend avoiding this treatment because it has not yet been fully developed and standardized. This means you cannot be sure of what your dose contains.

With further research, however, it could become a useful treatment option. Read on to learn more about PRP and other options for treating OA.

The platelets in your blood contain growth factors. Scientists believe that injecting PRP growth factors from your own blood into an injured area will help tissues repair themselves by causing new cells to form.

In this way, PRP could help reverse existing tissue damage.

Evidence about using PRP to treat knee OA has not yet confirmed that it is a safe and effective option, and studies have produced conflicting results.

While many studies support its use, many others say PRP has no effect, according to a 2019 review.

A 2017 review looked at 14 randomized controlled trials with a total of 1,423 participants. Results suggested that PRP may help manage pain associated with knee OA.

The authors noted the following at 3-, 6-, and 12-month follow-ups:

Pain levels: Compared with placebos, PRP injections significantly reduced pain scores at each follow-up appointment.

Physical function: Compared with controls, PRP significantly improved physical function at these follow ups.

Adverse effects: Some people experienced adverse effects, but these were no more significant than those produced by other types of injection.

While the results appear promising, 10 of the 14 studies reviewed had a high risk of bias, and four had a moderate risk of bias.

More studies are needed to determine whether PRP could offer a suitable option to manage pain from OA of the knee.

PRP is an experimental therapy, and experts do not currently recommend its use. If you are considering PRP injections, start by asking your doctor for their advice.

Since PRP injections are experimental, there is limited evidence about how safe and effective they are. In addition, your insurance policy may not cover them.

Work closely with your doctor before starting any experimental treatments, and ensure that any provider is fully qualified to offer this treatment.

First, your doctor will draw a small amount of blood from your arm.

Then, theyll put the blood sample into a centrifuge to separate the components and obtain a concentrated suspension of platelets in plasma. At this point, variations in procedure may lead to different concentrations of the various components.

Next, the doctor will numb your knee and inject the PRP into the joint space in the knee. They may use ultrasound to guide the injection.

After resting a while, you will be able to go home. You should arrange for someone to drive you home, as there may be pain and stiffness after the injection.

After the procedure, your doctor may advise you to:

You may need to use crutches or a walking frame for a few days to keep the weight off of your knee.

Follow your physicians advice about follow-up appointments.

PRP uses your own blood, so experts say it is likely to be safe.

However, an injection into the knee joint can entail some risks, including:

The 2017 review mentioned above found that some people experienced:

However, the researchers noted that these were non-specific and no more significant than the side effects of other injections.

Moreover, the cost of this type of treatment can be high, and insurers may not cover it. Find out how much it is likely to cost before you go ahead.

Bear in mind also that there may be unforeseen adverse effects, due to the experimental nature of the treatment.

There are various ways to manage OA-related pain and other symptoms. Weight management and exercise are key long-term strategies, but other options can provide more immediate relief.

Learn more about the treatment options for OA.

PRP injections use your own blood to stimulate growth in injured tissues. There is some evidence that this treatment may help manage pain associated with OA of the knee, but not enough to confirm that it works.

Experts do not currently recommend PRP injections for OA of the knee, due to the lack of standardization at the preparation stage.

If you are considering PRP, be sure to discuss it first with your doctor and follow their advice. Remember that it is an experimental treatment that clinics can only provide off-label.

Can diet help manage OA of the knee?

See original here:
Platelet-Rich Plasma for the Knee: Does It Work?

Tendinitis Treatment Market Overview By Growing Demands, Trends And Business Opportunities 2020 To 2027 – Jewish Life News

The Global Tendinitis Treatment Market is segmented on the lines of its technology, treatment, application and regional. Based on Type analysis it consists of Achilles tendinitis, supraspinatus tendinitis, tennis or golfers elbow, De Quervains tenosynovitis, and others. On the basis of treatment analysis includes diagnosis, therapy, shock wave therapy or surgery, medical devices, devices, and others. Diagnosis is again classified as physical examination, imaging tests, ultrasound, Magnetic Resonance Imaging (MRI) Scans, and others. Therapy is further segmented as non-pharmacological and pharmacological therapy. Non-pharmacological therapy includes rest therapy, heat & cold therapy, occupational therapy, physical therapy, and others. Pharmacological therapy includes OTC drugs or pain relievers, corticosteroids injections, platelet-rich plasma (PRP), and others. Medical devices segment is again segmented as mechanical band, support tape, pre-cut strips, continuous rolls, and others. On the basis of end user analysis it covers hospitals, clinics, medical research centers, academic institutes, and others. The Global Tendinitis Treatment Market on geographic segmentation covers various regions such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Each geographic market is further segmented to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, India, Brazil, and GCC countries.

FYI, You will get latest updated report as per the COVID-19 Impact on this industry. Our updated reports will now feature detailed analysis that will help you make critical decisions.

The Global Tendinitis Treatment Market is expected to exceed more than US$8066.0 Million by 2024 at a CAGR of 7% in the given forecast period.

You Can Browse Full Report: https://www.marketresearchengine.com/tendinitis-treatment-market

The scope of the report includes a detailed study of global and regional markets on Tendinitis Treatment Market with the reasons given for variations in the growth of the industry in certain regions.

Tendinitis is the irritation of the ligament, thick strings that attache the muscles deep down. The aggravation happens because of sudden damage to the ligament, monotonous development or sickness condition, for example, diabetes, rheumatoid joint pain, gout, Reiters disorder or lupus. If there should be an occurrence of patients with gout, the uric corrosive precious stones show up in the ligament sheath prompting rubbing. Tendinitis is observed to be pervasive among competitors and is one of the normal game wounds in wear players, particularly tennis, golf and others. Different pharmacological and non-pharmacological medications are accessible for the treatment of tendinitis. Non-Steroidal Anti-incendiary Drugs (NSAIDs) constitute the preparatory treatment alternatives. Different medicines including active recuperation, rest, and word related treatment. Surgery is the final resort for tendinitis, and is just prescribed if there should be an occurrence of extreme harm to the ligament that cant be dealt with utilizing pharmacological treatment alternatives.

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Pfizer (U.S.), AstraZeneca (U.K), Bayer (Germany), Abbott (U.S.), Merck & Co. Inc. (Germany), GlaxoSmithKline plc (U.S.), Boehringer Ingelheim Pharmaceuticals, Inc. (Germany), Teva Pharmaceutical Industries (Israel). Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and current developments.

The Global Tendinitis Treatment Market has been segmented as below:

The Global Tendinitis Treatment Market is Segmented on the lines of Type Analysis, Treatment Analysis, End User Analysis and Regional Analysis. By Type Analysis this market is segmented on the basis of Achilles tendinitis, Supraspinatus tendinitis, Tennis or golfers elbow, De Quervains tenosynovitis and Others. By Treatment Analysis this market is segmented on the basis of Diagnosis its covers Physical examination, Imaging tests, Ultrasound, Magnetic Resonance Imaging (MRI) Scans & Others. Therapy its covers Non-pharmacological therapy likes Rest therapy, Heat & cold therapy, Occupational therapy, Physical therapy & Others. Pharmacological therapy likes OTC drugs or pain relievers, Corticosteroids injections, Platelet-rich plasma (PRP) & Others. Shock wave therapy or surgery its covers Medical devices, Mechanical band, Support tape, Pre-cut strips & Others. Devices like Others.

By End User Analysis this market is segmented on the basis of Hospitals sector, Clinics sector, Medical research centers sector, Academic institutes sector and Others sector. By Regional Analysis this market is segmented on the basis of North America, Europe, Asia-Pacific and Rest of the World.

This report provides:

1) An overview of the global market for Tendinitis Treatment Market and related technologies. 2) Analyses of global market trends, with data from 2015, estimates for 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2024. 3) Identifications of new market opportunities and targeted promotional plans for Global Tendinitis Treatment Market. 4) Discussion of research and development, and the demand for new products and new applications. 5) Comprehensive company profiles of major players in the industry.

Request Sample Report: https://www.marketresearchengine.com/tendinitis-treatment-market

Reasons to Buy this Report:

1) Obtain the most up to date information available on all Global Tendinitis Treatment Market. 2) Identify growth segments and opportunities in the industry. 3) Facilitate decision making on the basis of strong historic and forecast of Global Tendinitis Treatment Market data. 4) Assess your competitors refining portfolio and its evolution.

The major driving factors of Global Tendinitis Treatment Market are as follows:

The restraining factors of Global Tendinitis Treatment Market are as follows:

Other Related Market Research Reports:

Tissue Regeneration Market is Expected to Grow US$ 60 Billion By 2022

Hyaluronic Acid Based Dermal Fillers Market is expected to exceed more than US$ 14.9 Billion by 2024

Sample Preparation Market Key Enhancement, Product Overview and Share Forecasted to 2024

Media Contact

Company Name: Market Research Engine

Contact Person: John Bay

Email: [emailprotected]

Phone: +1-855-984-1862

Country: United States

Website: https://www.marketresearchengine.com/

Read the original here:
Tendinitis Treatment Market Overview By Growing Demands, Trends And Business Opportunities 2020 To 2027 - Jewish Life News

Living Well: PRP: A Promising Treatment – The Daily Progress

While its not considered to be a miracle cure, platelet-rich plasma (PRP) has emerged in recent years as a useful new treatment option for some patients. Injecting PRP into certain inflamed or damaged areas of the body can help relieve pain and, in some cases, may enhance the bodys natural healing processes to help speed up recovery.

Undergoing a PRP treatment is fairly simple. All thats involved is a consultation, a blood draw and an injection. This often can be done in the same office visit.

Platelets are the blood cells that help the body control bleeding by forming clots, but platelets also naturally contain a huge amount of growth factors, which can act as healing agents. When those growth factors are injected into damaged structures, they can activate and enhance the bodys natural healing process.

PRP injection is especially effective in cases of inflammatory tendinitis, such as Achilles tendinitis, tennis elbow, and tendinitis of the rotator cuff and knee, according to Matthew Panzarella, MD, with the Sentara Sports Medicine Center.

PRP is a therapy we may consider if other conservative treatmentssuch as rest, physical therapy and icing, for examplehave proven ineffective, he says. Theres a lot of good data showing that PRP helps with inflammatory tendon problems, and in some cases it can help a patient delay or even avoid surgery.

In addition to healing tendons, the FDA-approved PRP technique can be used in certain cases to help heal damaged muscles and ligaments, and it can help relieve pain associated with cartilage tears and arthritis.

Superconcentrated Healing Platelets

The key to how PRP works lies in superconcentration of the platelets. As part of the treatment, about 15 milliliters (approximately 1 fluid ounce) of the patients blood is taken from the arm. The blood sample is then put in a centrifuge and spun down to separate the platelets from the plasma. The spinning process superconcentrates the platelets, which are then injected into the injured area of the patients body.

Physicians like Dr. Panzarella inject the PRP into the target site with the assistance of ultrasound guidance, which permits them to see exactly where the needle is being placed. The use of ultrasound guidance helps to ensure that the platelets are going directly into the damaged area where theyre most needed.

What Platelet-Enriched Plasma Canand CannotDo

Dr. Panzarella notes that patients often ask if PRP can help regrow or regenerate torn or arthritic cartilage.

The answer is no, he says. Even though platelets have growth factors, they wont regrow damaged or torn cartilage. But PRP therapy can still help with reduction of pain and inflammation in cases of torn and damaged cartilage. Platelets have a natural anti-inflammatory property, and PRP can help reduce inflammation and its associated pain in many cases of arthritis, torn meniscus and similar cartilage problems.

In cases where PRP seems to have a direct healing effect on structures like torn tendons and torn ligaments, the effect is dependent on the extent of injury.

Who is a Candidate for PRP?

Dr. Panzarella considers a number of criteria in helping patients decide whether PRP is right for them. These criteria include the extent type and location of the injury, and in the case of arthritis, the level of severity. A patients medication list also can factor into whether they are a candidate for PRP. This discussion takes place during an initial office visit, when treatment options, including PRP, are considered.

If the patient is a good candidate, the next step is typically to schedule an MRI (magnetic resonance imaging) scan to determine the extent and precise nature of the patients problem. If the patient decides to go forward with PRP therapy, an outpatient office visit is scheduled, during which the patients blood will be taken and spun down to concentrate the platelets, and then the patient will receive the injection.

After the injection, patients follow up with their physician in a few weeks, and frequently are referred to rehabilitation, if appropriate.

Are There Any Risks Associated with PRP?

PRP injections involve little risk because the patient is receiving his or her own blood product, so there is no concern with mismatched blood typing, transmission of disease or risk of rejection.

Anytime you stick a needle under the skin, theres a risk of infection, says Dr. Panzarella. But that risk is very lowwe clean the injection site really well.

Probably the biggest risk with PRP is that the treatment may not work. Dr. Panzarella points out to his patients that there are no guarantees with PRP, and insurance does not currently cover the cost of the procedure.

To help ensure that their patients have the best outcome possible with PRP, physicians have some recommendations for their patients.

I ask patients not to take any anti-inflammatory medications like ibuprofen, naproxen or meloxicam for 48 hours before their injection, and for a week afterwards, says Dr. Panzarella. Certain chemicals in nonsteroidal anti-inflammatory drugs like these can inhibit the release of healing elements from the platelets.

If you think you might benefit from PRP or have a sports related injury and need an appointment, call the Sentara Sports Medicine Center at 434-654-5575.

Originally posted here:
Living Well: PRP: A Promising Treatment - The Daily Progress

What Are the Different Types of Knee Injections? Pain Management – MedicineNet

What are knee injections? Knee injection is performed to treat the pain arising from various diseases of the knee joint.

Knee injection is a procedure in which medications are injected into the knee joint to treat the pain due to various causes.

There are different types of knee injections. The most common type of intra-articular knee injection is corticosteroids. Other agents used are hyaluronic acid, infliximab, Botox (botulinum neurotoxin), and platelet-rich plasma (PRP).

Knee pain and stiffness can be debilitating and difficult to treat. Knee conditions may negatively affect the quality of life and emotional wellbeing.

Weight management, exercise, physiotherapy, medications, knee injections, and surgery are some of the approaches used to treat knee pain.

Knee pain can result from ligament or tendon injury, fracture, cartilage loss in osteoarthritis, and inflammatory conditions such as inflammatory arthritis orseptic arthritis. Knee pain can also be due to joint malalignment or dysfunction and referred pain from other areas.

Diseases of the knee can be diagnosed based on

Knee injection is performed to treat the pain arising from various diseases of the knee joint. The type of medication injected and the frequency depends on the condition being treated. Based on the diagnosis and extent of the disease, the doctor would recommend a treatment plan.

Indications for the various agents used for knee injections are as mentioned below.

Steroid injections help to relieve pain and inflammation in individuals with:

Infliximab suppresses inflammation and can be used to treat the following:

Hyaluronic acid (HA) is naturally present in the joints, eyes, and skin. HA levels decrease with age, leading to joint friction and arthritis. HA knee injections lubricate the joint, decrease friction, decrease impact, delay joint aging, reduce pain, and stiffness. HA is used in the treatment of the following:

Knee injection is a relatively quick procedure and may be performed under local anesthesia to avoid pain. A needle of appropriate size and length connected to a syringe is introduced into the joint and the medication is injected. Radiological guidance may sometimes be used to aid injection.

After the procedure, the patient would need to rest for a few minutes, and then they can resume normal activities. Patients may experience pain, swelling, and bruising, which resolve in a few days. Ice packs and pain killers can help reduce pain and bruising.

The time taken for the knee injections to work depends on the medication injected. Different medications have different durations of onset and longevity.

Complications are rare and are typically resolved. Some common complications are:

Medically Reviewed on 7/10/2020

References

Medscape Medical Reference

Read the original post:
What Are the Different Types of Knee Injections? Pain Management - MedicineNet

Patient-Reported Outcomes After Platelet-Rich Plasma, Bone Marrow Aspirate, and Adipose-Derived Mesenchymal Stem Cell Injections for Symptomatic Knee…

Objective:The objective of this study was to compare platelet-rich plasma (PRP), bone marrow aspirate concentrate (BMAC), and adipose-derived mesenchymal stem cell (MSC) injections in the treatment of osteoarthritis (OA) of the knee using functional scores.

Methods:A total of 89 patients with painful knee OA were included in this study. Patients were assigned to one of the 3 treatments according to severity of OA as indicated by symptoms and radiography to PRP (stage I), BMAC (stage II), or adipose-derived MSC (stage III). Clinical assessment was performed using the Knee Society Score, which combines the Knee Score, based on the clinical parameters, and the Functional Score, and IKDC score. Surveys were completed at preoperative and at 90, 180, and 265 days postoperative. The follow-up responses were compared with baseline and between treatment groups.

Results:Treatment with PRP, BMAC, and adipose-derived MSC included 29 (32.6%), 27 (30.3%), and 33 (37.1%) patients, respectively. For the total group, median age was 61 years (range: 22-84 years). Score values were comparable among treatment groups at baseline. Statistically significant improvement was observed in the 3 groups according to the 3 scores at all time points during follow-up compared with baseline. No difference was found among treatment type.

Conclusions:Our findings support previous reports and encourage further research on the use of these cost-effective treatments for OA of the knee.

Keywords:Platelet-rich plasma; adipose-derived mesenchymal stem cell; bone marrow aspirate concentrate; knee; osteoarthritis.

See the original post:
Patient-Reported Outcomes After Platelet-Rich Plasma, Bone Marrow Aspirate, and Adipose-Derived Mesenchymal Stem Cell Injections for Symptomatic Knee...

These Are the Top Plastic Surgery Trends of the Last Decade, According to Top Surgeons – NewBeauty Magazine

Getty Images / Image Used for Illustrative Purposes Only

In celebration of World Plastic Surgery Day, we spoke to 11 leading plastic surgeons about their favorite trends of the last 10 yearsits incredible to think how the field has evolved since then. One thing stands out among all the responses we received: The move toward less-invasive and more natural is the trend thats changed the plastic surgery industry and is here to stay for good.

1. One of the biggest trends is microfat injections to the face, which allow for better contouring, either alone or with facial surgery, to prevent an over-operated, pulled look. Another trend I like is using an individualized approach to get the most natural result, in spite of the most extreme results you see on social media. Most patients want a natural appearance that doesnt say plastic surgery all over it, rather than excessive pulling and tightening. The combination of adding where its deficient and removing where its redundantmakes for a natural-looking outcome. La Jolla, CA plastic surgeon Robert Singer, MD

2. My favorite trend is blepharoplasty and the correction of festoons and malar bags (the puffiness below the lower eyelids and the bags between the lower eyelids and midface). These are challenging and difficult procedures, and most plastic surgeons do not want get involved with them. Festoons and malar bags could present in childhood, but the majority of them present later in life because of the laxity of the muscle around the eyes (orbicularis muscle). For their correction, we make an incision below the eyelashes, release ligaments that are boundaries of the festoons, and tighten the orbicularis muscle. New York plastic surgeon Mokhtar Asaadi, MD

3. The biggest trend over the past decade within the area of facial plastic surgery is the continuous shift toward a desired natural appearance after surgical rejuvenation. Many of the most popular cosmetic facial procedures are now minimally invasive. Patients are gravitating toward these types of treatments, which improvethe appearance of theface and skin, making them look younger but not different. New York facial plastic surgeon Konstantin Vasyukevich, MD

4. The use of PRP (platelet-rich plasma) in facial rejuvenation because it allows us to harness the regenerative properties of the patients own blood to restore youthfulness to their face in the most natural-appearing way. It is such a powerful anti-aging tool. Johns Creek, GA plastic surgeon Myla Bennett, MD

5. My favorite plastic surgery trend for the last decade is body contouring using minimally invasive techniques. This allows us to sculpt the body by removing unwanted fat from areas of the body using modern liposuction techniques and add it to other areas to augment and accentuate the curves of the body. The combination of subtraction in some areas and addition to adjacent areas is much more powerful than the traditional methods 10 years ago, which focused on only removing fat from unwanted areas. New York plastic surgeon Craig A. Baldenhofer, MD

6. My favorite plastic surgery trend has been the shift toward a more holistic approach to our field, including adding diet, skin care, wellness, and noninvasive treatments to what we offer and recommend to patients. Troy, MI plastic surgeon Anthony Youn, MD

7. I have enjoyed the trend of more natural-looking plastic surgery, especially with regard to breast implant sizing. Since bigger is not always better, its important toconsider each patients body type. Careful exam, breast measurements and 3-D video-imaging help us determine the ideal breast implant size to meet our patients goals. Houston plastic surgeon Kriti Mohan, MD

8. Im seeing more people combining surgery with nonsurgical treatments to create more comprehensive facial rejuvenation. Tremendous advances have been made in the last decade, improving skin care and nonsurgical treatments of the face and neck. These treatments include better, longer-lasting fillers, neurotoxins such as Botox, lasers, and radio-frequency devices. Another highly-effective complement to body-contouring surgery is the use of a persons own fat to improve fullness in areas where fat is lacking. Fat grafting is now a common addition to facial rejuvenation surgery, restoring areas of loss due to aging. Houston plastic surgeon Christopher Patronella, MD

9.By far, the greatest innovation and trend that I have seen over the last decade include combination of nonsurgical techniques and threadlifting. The use of combination approaches, or Stackable Treatments, have revolutionized nonsurgical enhancement to the face and body, and I am proud to have been part of the conceptual development and advancement. Threadlifting fits into this category as well, and it really has changed the way I do facelift surgery to create a more natural result, and my colleagues have benefited from the lessons threadlifting has taught us about natural movement of the face and neck. The technical advancement that my research has shown paves the way for future advancement and innovation in nonsurgical lifting of the face, neck and body. Chicago plastic surgeon Julius Few, MD

10. Reoperative breast implant surgery has become a trend over the last decade with regards to women wanting to maintain their outcomes or upgrade to the newest-generation silicone gel implants from aging saline-filled implants of yesteryear. Eugene, OR plastic surgeon Mark Jewell, MD

11. My favorite plastic surgery trend over the past decade has been the use of noninvasive treatments combined with surgical procedures. At Ciaravino Total Beauty, our breast augmentation patients will often get lip injections, skin-care treatments, Botox, CoolSculpting or Emsculpt, too. These combined treatments can make for really beautiful transformations. Houston plastic surgeon Michael Ciaravino, MD

At NewBeauty, we get the most trusted information from the beauty authority delivered right to your inbox

Find a NewBeauty "Top Beauty Doctor" Near you

View post:
These Are the Top Plastic Surgery Trends of the Last Decade, According to Top Surgeons - NewBeauty Magazine

Could Joe Maddon Lead The Angels To Cubs-like Success In 2020? – Prospect Insider

The Los Angeles Angels have been in the doldrums recently four straight losing seasons and just one playoff appearance in the Mike Trout era. Enter Joe Maddon, who guided the Cubs to four postseasons in five years and their first World Series win since Teddy Roosevelt was president. Could Maddon lead the Angels to Cubs-like success in 2020?

How much a manager actually influences a baseball teams win-loss record is a never-ending topic of debate for fans and bloggers. Did the team succeed thanks to their skippers field generalship? On the other hand, was it a talented roster? For me, the answer is its usually a blend of both.

No manager couldve made the hapless Detroit Tigers a winner last year. But a skipper could potentially be a positive or negative difference-maker for teams on the fringe of contention. The issue at hand is whether Maddons new squad has the talent to contend this year.

Certainly, Angels GM Billy Eppler tried his best to give Maddon more to work with than predecessor Brad Ausmus had in 2019. In the offseason, Eppler signed all-star third baseman Anthony Rendon, thanks to owner Arte Moreno opening his checkbook. The fifth-year GM also managed to add several other recognizable veterans pitchers Dylan Bundy, Julio Teheran, and Matt Andriese, plus catcher Jason Castro.

So, did Eppler give Maddon the necessary pieces to make the Angels a viable contender in 2020? Lets walk through the roster the 66-year-old skipper will be working with to determine the answer.

Availability was an ongoing problem for the Angels in 2019. No starter remained in the rotation for the entire season with this years Opening Day starter, Andrew Heaney, leading the staff with 18 starts and 95.1 innings.

Compounding matters, Angel pitchers made just 22 quality starts fewest by a team in any season, including campaigns shortened by work stoppage. The league-average for quality starts last season was 51 with the Astros leading MLB with 89. In fact, six pitchers made more quality starts than the Halos.

Pitchers With More Quality Starts Than Angels in 2019

Before Summer Camp began, the projected rotation included Heaney, Shohei Ohtani, Julio Teheran, Dylan Bundy, and GriffinCanning. With Ohtani coming off Tommy John surgery, the Angels will employ a six-man rotation with a gaggle of pitchers vying for the final spot. Initially in the mix were Matt Andriese, Flix Pea, DillonPeters, plus a trio of youngsters Jaime Barra, Patrick Sandoval, and Jos Suarez. But things have already changed.

As already noted, injuries played a significant role in the Angels rotation woes in 2019. Health issues are once again affecting the staffs readiness for the upcoming season.

Teheran reportedly has COVID-19 with mild symptoms, but may return soon. Still, its unlikely the 29-year-old is ready for the start of the season. Ironically, availability has been the nine-year veterans strength. Since 2013, only four pitchers have made 30-plus starts in every season Teheran, Jose Quintana, Jon Lester, and Mike Leake.

On that note, Suarez is one of several Angels on the 10-day IL for undisclosed reasons. Whether its COVID-related or something else remains unknown. As with Teheran, the delay diminishes the odds of the 22-year-old being ready for Opening Day.

Peters is also on the 10-day IL, but thats not a surprise as with Teheran and Suarez. The 27-year-old entered camp expecting to miss a few weeks with a lingering oblique strain from Spring Training. Last season, Peters ERA and xwOBA ranked in the bottom 10-percent of pitchers facing 250-plus hitters.

A pair of currently healthy pitchers likely to receive scrutiny due to recent arm issues are Heaney and Canning.

Heaney has made 20-plus starts just once in five seasons with Los Angeles when he started 30 contests in 2018. Last year, it was elbow and shoulder issues slowing the southpaw. When available, he was brilliant at times striking out 10-plus hitters in four games. Conversely, the 29-year-old didnt reach the sixth inning in half of his outings.

After encountering elbow issues last August, Canning received a platelet-rich plasma (PRP) injection into the elbow in March. The 24-year-old resumed throwing a month later and reported to camp proclaiming his readiness for the season. Good news for both pitcher and team, although Ohtani and Heaney had PRP injections before eventually undergoing TJ surgery.

On a more positive note, injuries undermined Bundys early career, but hes averaged 30 starts since 2017. His 4.83 ERA during this period isnt appealing, yet the 27-year-olds .320 xwOBA was identical to Jeff Samardzija and Marco Gonzales and slightly better than league-average for starters (.324). This suggests pitching home games in hitter-friendly Camden Yards affected right-handers conventional stats.

The short-term loss of Suarez and Peters from early consideration benefits Andriese, who began his career as a starter with the Rays. However, the 30-year-old was an effective full-time reliever with Arizona in 2019. Perhaps Maddon uses the five-year veteran in a variety of roles.

Pea logged 96.1 innings as a starter and reliever before suffering a torn ACL in his right knee last August. Considering his .308 xwOBA as a reliever was significantly better than as a starter (.370), Maddon could piggyback the 30-year-old behind the games starter early in the season or use him as a swing-man.

Sandoval and Barra, both 23-years-old, scuffled last season. Sandoval was a rookie last year, but Barra made 26 starts with a 3.41 ERA as a freshman in 2018. A return to his rookie form would benefit both Barra and the Halos.

Last years bullpen did a commendable job considering starters rarely delivered quality starts and pitched the fewest total innings in the majors. Considering the potential issues the rotation may be facing this year, expect Maddon to turn to his relief corps early and often.

The main contributors to the bullpen in 2019 were closer Hansel Robles, Ty Buttrey, Cam Bedrosian, and No Ramrez. Robles, Bedrosian, and Ramrez were strong. Buttrey began the season well, but slipped during the second half. All return in 2020.

Heading into camp, the leading relievers are Robles, Buttrey, Bedrosian, Ramrez, Ryan Buchter, Justin Anderson, and Keynan Middleton, whos returning from TJ surgery. Candidates to fill out the bullpen include Kyle Keller, Luke Bard, Taylor Cole, Jos Quijada, Parker Markel, Jacob Rhame, and Hector Yan.

The left-handed throwing Quijada is also on the 10-day IL for undisclosed reasons. Perhaps this doesnt matter as much as it did in the past, but the Venezuelan, along with Buchter and Yan, are the only southpaw relievers on the 40-man roster. Furthermore, Yan hasnt pitched above Class-A level.

Many familiar faces return this year with one significant addition. The longest tenured infielder with the team is Albert Pujols, wholl play either first base or designated hitter depending on Ohtanis availability. The 40-year-olds offensive production has been below league-average since 2016. Is it possible Maddon would consider reducing the future Hall of Famers playing time? Bench options include Matt Thaiss, who also possesses third base experience, and rookie Jared Walsh.

Fun Fact: Jared Walsh made 12 relief appearances and saved one game for Class-AAA Salt Lake in 2019. The left-handed thrower also pitched in five games for the Angels.

David Fletcher and Tommy La Stella should be the main stakeholders at second base. Last year, Fletcher paced the team in games played (154) and doubles (30) with only Trout having a higher AVG and OBP. Adding to his value, the 25-year-old demonstrated positional versatility with 20-plus starts at second base, shortstop, third base, and left field.

La Stella was enjoying a breakout season in 2019 earning his first All-Star selection. Unfortunately, the 30-year-old suffered a fractured tibia in early-July, which sidelined him until late September. La Stella also has third base experience.

After posting career bests in AVG, OBP, and OPS+ in 2018, injuries limited the offense and availability of Andrelton Simmons last season. The 30-year-old former Gold Glove winner will be looking to rebound during an abbreviated walk year.

Holding down the hot corner is Rendon, who the team inked to a seven-year/$245 million contract. Last season, the NL MVP finalist set career highs in doubles, home runs, AVG, OBP, SLG, OPS+, and WAR.

The Angels reportedly attempted to trade Luis Rengifo to the crosstown rival Dodger in exchange for outfielder Joc Pederson in the offseason. Entering camp, the 23-year-old seemed like logical fit as back-up middle-infielder before disappearing to the 10-day IL recently. During his rookie season in 2019, switch-hitter started 90 games at second base and 11 contests at shortstop.

Theres still a chance the Rengifo is ready for Opening Day. If the team were to look elsewhere for an infield reserve, potential candidates include non-roster invitee Arismendy Alcntara plus minor leaguers Jose Rojas, Jahmai Jones, and Elliot Soto.

As with the infield, most of the usual suspects return from 2019 with the notable exception of Kole Calhoun, who signed with Arizona. But theres an outside chance a highly-touted prospect joins a future Hall of Famer in the outfield this year.

Lower leg injuries limited left fielder Justin Upton to just 63 games and his worst offensive production since his rookie season in 2007. Upton slashed a lackluster .215/.309/.416 with 12 home runs in 256 plate appearances. The Angels certainly need a bounce back season from the 32-year-old.

Trout, last years MVP, returns in center field. The New Jersey native slashed .291/.438/.645 with 45 home runs and led the majors in OPS+ for a third consecutive season. Its worth noting the 28-year-old has intimated he may not play this year to mitigate the risk of COVID-19 exposure for his wife and unborn child.

In Uptons absence, Brian Goodwin played a career-high 146 games and delivered personal bests in doubles (29), home runs (17), and OPS+ (109). The 29-year-old will begin the season as the everyday right fielder, although its plausible top prospect Jo Adell makes the team and eventually supplants Goodwin.

Still, Adell wasnt expected to be on the Opening Day roster in March and isnt on the 40-man roster. The loss of the minor league season may delay the 21-year-olds MLB debut until next year.

Michael Hermosillo likely serves as the fourth outfielder. The 25-year-old has limited big-league experience since first debuting in 2018, but he can play anywhere in the outfield. Its reasonable to expect Fletcher to see playing time in the outfield. Former first round pick Taylor Ward may be in the mix for a backup job also.

When hes not pitching, Ohtani will serve as primary designated hitter. Although he couldnt pitch last season, the 26-year-old delivered 43 extra-base hits, including 18 home runs, in 106 games. He also lead the team with 5 triples and 12 stolen bases. As noted earlier, Pujols likely fills the DH role when Ohtani is on the mound or unavailable due to pitching responsibilities.

Free agent addition Jason Castro figures to be the regular catcher with Max Stassi likely spotting Castro. With Minnesota last season, the left-handed hitting Castro platooned with MitchGarver. One area to watch; Castros career .553 OPS against southpaws is much lower than against right-handers (.750). Castro has a reputation as a sound defender and pitch framer.

Stassi is strong defensively, but the right-handed hitter hasnt enjoyed much success at the plate during a 183-game career spanning seven seasons. The teams third catcher is Anthony Bemboom. The left-handed hitting Bemboom, who is solid behind the plate, made his MLB debut last year at age-29.

While the addition of Rendon and Ohtanis return to the mound provides a boost, starting pitcher health once again looms as a potential showstopper. Perhaps the truncated 60-game season diminishes the importance of a deep rotation. If thats the case, Maddon may be able to compensate for his staffs shortcomings by having a quick hook with struggling starters. Thats assuming the bullpen performs as it did in 2019.

Still, the Angels chronic difficulties with starting pitcher availability is tough to overlook. For this reason, I believe the AL West is out of reach, even with Maddon at the helm. Maybe the three-time Manager of the Year can elevate to fringe contender status, but its tough envisioning the team earning a wild card berth in the highly competitive American League.

This disappoints me since Id like to see Trout, baseballs best player, add meaningful October baseball to his already-brimming Hall of Fame rsum.

My Oh My

(Photo of Joe Maddon AP)

In 2014, Luke joined the Prospect Insider team and is now a contributor at HERO Sports also. During baseball season, he can be often found observing the local team at T-Mobile Park.

You can follow Luke on Twitter @luke_arkins

Read the original:
Could Joe Maddon Lead The Angels To Cubs-like Success In 2020? - Prospect Insider